KB Financial Group, Inc. vs Zoetis Inc — how do they compare? KB Financial Group, Inc. trades at $118.91 (market cap $38.56B), while Zoetis Inc trades at $75.61 (market cap $31.95B). The key difference: KB Financial Group, Inc. is the larger of the two by market cap, and Zoetis Inc pays the higher dividend (2.78%). Which is the better fit depends on your goals.
| KB | ZTS | |
|---|---|---|
Market Cap | $38.56B | $31.95B |
Sector | Financials | Health |
52-Week High | $123.25 | $156.76 |
52-Week Low | $77.50 | $71.91 |
Dividend Yield | 2.72% | 2.78% |
Enterprise Value | — | $39.24B |
Signals from Pluang's Aura AI — not financial advice
KB Financial Group (KB) trades at $115.23, down 3.47% today, but maintains a bullish technical outlook with strong moving average signals. The company shows solid fundamental performance with a 27.82% net income margin and consistent earnings beats in recent quarters. Revenue growth has been steady, reaching $21.23T in 2025, while analyst sentiment is mixed with a 33.33% buy rating amid broader hold consensus. Recent news highlights diversification into non-banking segments, which now contribute 43% of earnings.
The stock presents a balanced outlook with upside from earnings growth and diversification efforts, but faces risks from volatile cash flows and macroeconomic pressures. Investors should weigh the attractive valuation metrics against execution risks in non-banking expansion. The current price near recent highs suggests cautious optimism is warranted.
Zoetis (ZTS) trades at $76.05, down 0.67% on the day, with a neutral technical signal and bearish moving averages. The company maintains strong fundamentals with a 28.03% net income margin and 67.75% ROE, though Q1 2026 earnings missed expectations. Recent news highlights multiple securities class action lawsuits filed against the company, creating near-term uncertainty despite the launch of new product Lenivia in Canada and EU markets.
The stock presents a mixed outlook with attractive valuation metrics (P/E 12.55) and analyst consensus price target of $101.43 suggesting 33% upside potential. However, legal challenges and the recent earnings miss pose significant near-term risks. Institutional sentiment remains divided with 47% buy ratings versus 53% hold ratings, indicating cautious optimism amid legal headwinds.
Trailing returns across standard periods
Latest headlines on both assets
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →